Abstract: Brucellosis is an infectious disease that brings great economic burdens for developing countries. The vaccine S2 which is an attenuated Brucella suis (B. suis) strain has been used on a large scale in China. However, the immunity induced by S2 declined relative to those vaccinated with Rev-1 and S19 vaccines. Moreover, the vaccine S2 cannot differentiate natural from vaccinated infection. Therefore, a safer and more potent B. suis vaccine is needed. In this study, a vjbR mutant of B. suis (B. suisΔvjbR) was constructed overcome these drawbacks. The B. suisΔvjbR strain showed reduced survival capability in RAW264.7 macrophage and mice and induced high protective immunity in mice. In addition, B. suisΔvjbR induced an anti-Brucella-specific IgG (immunoglobulin G) response and stimulated the expression of gamma interferon (INFγ). Further, the vjbR antigen allowed serological differentiation between natural and vaccinated infection in mice. Therefore, B. suisΔvjbR was suggested as a safe and efficacious live vaccine candidate against virulent Brucella suis (B. suis) infection.
Fei Guo, Junbo Zhang, Chuangfu Chen, Yuanzhi Wang and Hui Zhang, 2014. Development and Evaluation of Vaccines in the Mice Using Brucella suis (B. suis) Deletion Mutant of the vjbR Gene. Journal of Animal and Veterinary Advances, 13: 306-312.